Societe D'expansion Scientifique Expansia

Genzyme Corporation

Les Laboratoires Servier

Sangstat Medical Corporation

Societe D'expansion Scientifque Expansia

Bernard Calas

Michel Follet

Roland Buelow

Robert Jacquier

Jacques Daunis

Christian Aspisi

Joseph Parello

Pierre Renard

Bruno Pfeiffer

Dominique Manechez

G&egrave;rard Grassy

G&eacute;rard Grassy

Jean Mery

Alain Chavanieu

Hanitra Naharisoa

Gèrard Grassy

Cyril Sarrauste De Menthiere

Novel oligonucleotides comprising a sequence derived by a computer program are provided for inhibiting cytotoxic activity of lymphocytic cells, inhibiting production of inflammatory cytokines and inflammatory responses associated with those cytokines, inhibiting the activity of heme-containing enzymes and delaying the onset of an autoimmune disease. By combining the subject compositions with mixtures of cells comprising lymphocytic cells and cells which would otherwise activate the lymphocytic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a variety of other groups or compounds for varying the activity of the subject composition. The subject compositions may be administered by any convenient means to inhibit lymphocytic attack on tissue, particularly involved with xenogeneic or allogeneic transplants or to inhibit the production of inflammatory cytokines and inflammatory responses associated therewith. The subject compositions may also be used in the inhibition of the activity of heme-containing enzymes.

Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Novel oligopeptides comprising a sequence derived by a computer program are provided for use in inhibiting cytotoxic activity of lymphocytic cells, inhibiting the production of inflammatory cytokines and inflammatory responses associated with those cytokines, inhibiting the activity of heme-containing enzymes and delaying the onset of an autoimmune disease in a mammal at risk of developing the disease. By combining the subject compositions with mixtures of cells comprising lymphocytic cells and cells which would otherwise activate the lymphocytic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a wide variety of other groups or compounds for varying the activity of the subject compositions. The subject compositions may be administered by any convenient means to a host to inhibit lymphocytic attack on tissue, particularly involved with xenogeneic or allogeneic transplants or to inhibit the production of inflammatory cytokines and inflammatory responses associated therewith. The subject compositions may also be used in the inhibition of the activity of heme-containing enzymes.

Peptide compounds analogues of the glucagon-like peptide-1 (7-37)

This invention relates to solid phase peptide synthesis. Solid phase peptide synthesis is accomplished on polyacrylic resins (such as those described in EP 0 079 812 and EP 0 081 408 which correspond to U.S. Pat. Nos. 4,436,874 and 4,439,545 respectively) by a method which includes in the coupling protocol steps of washing the resin in water and/or aqueous solution(s).

Solid phase peptide synthesis using a polyacrylic support in aqueous

The invention relates to new reticulated statistic acrylic copolymers that may be used in a very wide range of solvents (water, methylene chloride, chloroform, methanol, ethanol, dimethylformamide, pyridine,) stable between pH 1 and pH 14, to preparation process thereof and to their use in ion exchange chromatography.

Acrylic copolymers of N-acryloylpolymethyleneimines or

The present invention relates to new amino-functionalized acrylic copolymers, their preparation and their use in peptide synthesis.

Acrylic copolymers and their use in solid phase peptide synthesis

Growing community of inventors

Montpellier, France

Bernard Calas